Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
Japan
· Delayed Price · Currency is JPY 1,287.00
-8.00 (-0.62%)
May 20, 2025, 3:30 PM JST
TYO:2395 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Net Income | 4,925 | 6,974 | 7,759 | 8,183 | 4,175 | Upgrade
|
| Depreciation & Amortization | 2,611 | 1,867 | 1,600 | 1,177 | 1,187 | Upgrade
|
| Loss (Gain) From Sale of Assets | 228.8 | 84 | 56 | 246 | 642 | Upgrade
|
| Asset Writedown & Restructuring Costs | 78.13 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 130.89 | 31 | 1,321 | -1,058 | -1,173 | Upgrade
|
| Loss (Gain) on Equity Investments | -3,513 | -2,751 | -2,489 | -1,439 | -846 | Upgrade
|
| Other Operating Activities | 1,706 | 1,048 | 256 | -90 | -66 | Upgrade
|
| Change in Accounts Receivable | -870.53 | -956 | -937 | -480 | -343 | Upgrade
|
| Change in Inventory | -149.01 | -5,003 | -968 | -371 | -71 | Upgrade
|
| Change in Accounts Payable | -9.82 | -177 | -268 | -36 | -24 | Upgrade
|
| Change in Other Net Operating Assets | 2,109 | 989 | -2,326 | -180 | 1,265 | Upgrade
|
| Operating Cash Flow | 7,246 | 2,106 | 4,004 | 5,952 | 4,746 | Upgrade
|
| Operating Cash Flow Growth | 244.09% | -47.40% | -32.73% | 25.41% | 57.26% | Upgrade
|
| Capital Expenditures | -10,854 | -8,582 | -4,838 | -1,542 | -1,067 | Upgrade
|
| Sale of Property, Plant & Equipment | 4.21 | 5 | 11 | - | 1 | Upgrade
|
| Cash Acquisitions | - | -883 | -1,937 | 58 | - | Upgrade
|
| Divestitures | - | - | - | 1,142 | 1,242 | Upgrade
|
| Sale (Purchase) of Intangibles | -79.17 | -22 | -116 | -71 | -50 | Upgrade
|
| Investment in Securities | -771.65 | 2,625 | 1,018 | -4,194 | -804 | Upgrade
|
| Other Investing Activities | 8.96 | -50 | -68 | 2 | -1 | Upgrade
|
| Investing Cash Flow | -11,691 | -6,907 | -5,930 | -4,268 | -268 | Upgrade
|
| Short-Term Debt Issued | 2,916 | - | 4,083 | - | - | Upgrade
|
| Long-Term Debt Issued | 14,000 | 17,700 | 10,300 | - | 4,540 | Upgrade
|
| Total Debt Issued | 16,916 | 17,700 | 14,383 | - | 4,540 | Upgrade
|
| Short-Term Debt Repaid | - | -3,903 | - | -6 | -2,000 | Upgrade
|
| Long-Term Debt Repaid | -8,981 | -6,231 | -5,469 | -3,492 | -4,598 | Upgrade
|
| Total Debt Repaid | -8,981 | -10,134 | -5,469 | -3,498 | -6,598 | Upgrade
|
| Net Debt Issued (Repaid) | 7,935 | 7,566 | 8,914 | -3,498 | -2,058 | Upgrade
|
| Repurchase of Common Stock | -0.33 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -2,100 | - | - | - | - | Upgrade
|
| Dividends Paid | -2,100 | -2,073 | -2,485 | -827 | -207 | Upgrade
|
| Other Financing Activities | 79.07 | -175 | -163 | -586 | -206 | Upgrade
|
| Financing Cash Flow | 5,914 | 5,318 | 6,266 | -4,911 | -2,471 | Upgrade
|
| Foreign Exchange Rate Adjustments | 369.81 | 559 | 311 | 496 | 29 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -269.94 | 1 | -2 | - | - | Upgrade
|
| Net Cash Flow | 1,569 | 1,077 | 4,649 | -2,731 | 2,036 | Upgrade
|
| Free Cash Flow | -3,607 | -6,476 | -834 | 4,410 | 3,679 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 19.87% | 96.74% | Upgrade
|
| Free Cash Flow Margin | -11.13% | -24.48% | -3.32% | 24.85% | 24.35% | Upgrade
|
| Free Cash Flow Per Share | -86.64 | -155.56 | -20.03 | 105.93 | 88.37 | Upgrade
|
| Cash Interest Paid | 216.9 | 125 | 118 | 118 | 172 | Upgrade
|
| Cash Income Tax Paid | 2,013 | 1,223 | 1,437 | 1,014 | 479 | Upgrade
|
| Levered Free Cash Flow | -5,527 | -7,430 | -2,725 | 2,467 | 2,677 | Upgrade
|
| Unlevered Free Cash Flow | -5,401 | -7,344 | -2,647 | 2,546 | 2,792 | Upgrade
|
| Change in Net Working Capital | -1,055 | 3,208 | 2,571 | -359 | -1,141 | Upgrade
|
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.